|
Online Database of Chemicals from Around the World | Search | Submit | Advertise | |
Home >> Chemical Listing >> Stiripentol-d9>> Market Analysis Reports |
Market Analysis Reports of Stiripentol-d9 |
|
Global Market Report of Stiripentol (CAS 49763-96-4) December 2024 CAS 49763-96-4 Stiripentol Chemical Report & Database ... Consumption Report & Database definitions: Name: Stiripentol: Stiripentol; 4,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol Synonyms ... -96-4 APPLICATIONS: Chemical or Reaction Intermediate The Stiripentol Report & Database gives Market Consumption ... EC Number: 256-480-9 stiripentol Chemical Report & Database ... : 256-480-9 stiripentol Chemical Report & Database This stiripentol Chemical World ... listed. The substance covered (stiripentol) are classified by the Chemical ... Report & Database definitions: Name: stiripentol: stiripentol Chemical Registry number: 769198113929 EC ... Hyperoxaluria - Pipeline Insight, 2021 ... of Hyperoxaluria in phase III stage of development. Stiripentol: Biocodex Stiripentol is an orally active compound originated ... that inhibits several P450 cytochromes. Stiripentol developed by Biocodex is being studied in phase ... Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2021 Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2021 SUMMARY Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded ... Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY According to the recently published ... Global GABA Receptor Agonist Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024 Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. “Global GABA Receptor Agonist Drug Market, Dosage, Price & Clinical Pipeline Outlook 2024” Report Highlights: Global GABA Drugs Market Analysis by ... Global Dravet Syndrome Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023 ... , Depakene). Second line treatments include stiripentol (Diacomit), topiramate (Topamax), and the ... Primary Hyperoxaluria - Pipeline Insight, 2021 This report can be delivered to the clients within 24 Hours DelveInsight’s, “Primary Hyperoxaluria – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Primary Hyperoxaluria pipeline landscape. It ... Global Dravet Syndrome Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029 ... , Depakene). Second line treatments include stiripentol (Diacomit), topiramate (Topamax), and the ... Epilepsy Drugs Market Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (First Generation Anti-Epileptics, Second Generation Anti-Epileptics, and Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacy, Retail Pharmacy Stores, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) ... , lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, stiripentol, tiagabine, topirate, topiramate, vigabatrin, and ... Doose Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 ... medications, such as valproic acid, benzodiazepines, stiripentol, etc., for managing seizures and ... Dravet Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major Dravet syndrome markets reached a value of US$ 375.8 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 796.3 Million by 2034, exhibiting a growth rate (CAGR) of 7.07% during 2024-2034. The Dravet syndrome market has ... Piperonal Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type ... segment includes the production of Tadalafil, Stiripentol, Droxidopa, L-Dopa, and Atrasentan, among ... Dravet Syndrome Market Forecasts to 2032 – Global Analysis By Drug Type (Antiepileptic Drugs [AEDs], Cannabidiol-Based Drugs, Serotonin Modulators and Gene Therapy & Emerging Treatments), Treatment Type (Symptomatic Treatment, Ketogenic Diet and Vagus Nerve Stimulation [VNS]), Seizure Type, Distribution Channel and By Geography ... of medications, including valproate, clobazam, and stiripentol, which are routinely used in polytherapy ... |